 |
 | Patient Screening for Malignancy |
| |  | Patient Questionnaire with Cancer Warning Signs |
| | | When to Consider the Diagnosis of a Familial or Hereditary Cancer |
| | | Clinical Criteria of Sanderson and Ironside for Referral of a Patient for Exclusion of a Cancer of the Head or Neck |
| | | Risk Factors of Burgi et al for Non-AIDS Defining Cancers in an HIV-Positive Patient |
| Diagnostic Testing in Oncology |
| |  | Flow Cytometry for Estimation of S-phase Fraction |
| | | Flow Cytometry to Calculate the DNA Index |
| | | Histochemical Score for Immunohistochemical Tumor Markers |
| | | Indications for Performing Electron Microscopy on a Tumor |
| Tumors of the Head and Neck: Tumors of the Oral Cavity and Pharynx |
| | | Histologic Parameters and Prognosis in Squamous Cell Carcinoma of the Oropharynx |
| | | Prediction of Metastases to Cervical Lymph Nodes from Squamous Cell Carcinoma of the Tongue and Floor of the Mouth Based on the Histologic Malignancy Score and Vascular Invasion |
| | | Risk Factors for Malignant Neoplasm in the Adult Tonsil |
| | | Histopathologic Malignancy Score of Jakobsson et al in Squamous Cell Carcinoma of the Head and Neck |
| | | TNM Staging for Cancers of the Lip and Oral Cavity |
| | | T and N Integer Score (TANIS) Staging System for Squamous Cell Carcinoma of the Oral Cavity |
| | | Functional Severity Index and Extended Clinical Severity Staging System for Cancer of the Tongue or Floor of the Mouth |
| | | Risk Factors for Squamous Cell Carcinoma of the Lip |
| | | Risk Factors for Lymph Node Metastasis in Patients with Squamous Cell Carcinoma of the Lip |
| | | M.D. Anderson Risk Scores for Head and Neck Cancer Recurrence at the Primary Site and in the Neck |
| | | M.D. Anderson Risk Factors for Recurrence in Patients with Cancer of the Head and Neck |
| | | Predictors of Medow et al for Patients with Squamous Cell Carcinoma of the Head and Neck |
| | | TNM Staging for Cancers of the Hypopharynx |
| | | TNM Staging for Cancers of the Oropharynx |
| | | Pretreatment Probability Model of van den Broek et al for 2 Year Survival After Intra-arterial Chemoradiation in a Patient with Advanced Head and Neck Carcinoma |
| | | Pretreatment Probability Model of van den Broek et al for 2 Year Local Control After Intra-arterial Chemoradiation in a Patient with Advanced Head and Neck Carcinoma |
| | | Prognostic Factors of Argiris et al for a Patient with Recurrent or Metastatic Carcinoma of the Head and Neck |
| | | Histologic Features of Saywell and Weedon in Squamous Cell Carcinoma of the Lip Associated with Metastatic Disease |
| | | DIAGS Index of Mori et al for Predicting Lymph Node Metastases in a Patient with a Squamous Cell Carcinoma of the Oral Cavity |
| | | The Clinical Severity Staging System of Pugliano et al for Carcinoma of the Oral Cavity |
| | | Immunohistochemical Patterns of Zarovnaya and Black Distinguishing Pseudoepitheliomatous Hyperplasia (PEH) from Squamous Cell Carcinoma (SCC) |
| | | Prognostic Indicators of Le Tourneau et al for Survival in a Patient with a Squamous Cell Carcinoma of the Head and Neck |
| | | Grades of Ojiri et al for CT Scan Documented Response to Therapy of an Oropharyngeal Squamous Cell Carcinoma |
| | | Risk Factors of Garavello et al for Distant Metastases in a Patient with Squamous Cell Carcinoma of the Head and Neck |
| | | Risk Factors of Liao et al for Distant Metastases in a Patient with Squamous Cell Carcinoma of the Oral Cavity |
| Tumors of the Head and Neck: Tumors of the Paranasal Sinuses, Nasal Cavity and Nasopharynx |
| | | Classification Scheme of Ho for Nasopharyngeal Carcinoma |
| | | Prognostic Factors of Heng et al for Nondisseminated Nasopharyngeal Carcinoma |
| | | Model of Waldron and Witterick for Predicting Survival in a Patient with Paranasal Sinus Cancer Based on the Clinical Extent of the Primary Tumor |
| | | Istituto Nazionale per lo Studio e la Cura dei Tumori (INT) Classification of Malignant Ethmoid Tumors |
| | | TNM Staging for Cancer of the Maxillary Sinus |
| | | TNM Staging for Cancer of the Nasopharynx |
| | | TNM Staging for Cancer of the Nasal Cavity and Ethmoid Sinus |
| | | Prognostic Model of Leung et al for a Patient with Nasopharyngeal Carcinoma Based on Plasma EBV DNA Load and TNM Stage |
| | | Score of Grandi et al for Staging a Patient with Nasopharyngeal Cancer |
| | | Modified Kadish Staging System for Esthesioneuroblastoma (Olfactory Neuroblastoma) |
| | | Prognostic Scores of Neel et al for a Patient with Nasopharyngeal Carcinoma (NPC) |
| | | Histologic Grading Criteria of Hyams for Esthesioneuroblastoma (Olfactory Neuroblastoma) |
| | | Prognostic Index Score of Ong et al for Metastatic Nasopharyngeal Carcinoma |
| Tumors of the Head and Neck: Tumors of the Salivary Glands |
| | | TNM Classification and Staging of Salivary Gland Tumors |
| | | Prognostic Scores of Vander Poorten et al for Patients with Parotid Carcinoma |
| | | Revised TNM Classification and Staging of Salivary Gland Tumors |
| | | Grading Criteria of Goode et al for Mucoepidemoid Carcinoma of Salivary Glands (AFIP Criteria) |
| | | Grading Criteria of Brandwein et al for Mucoepidermoid Carcinoma of Salivary Glands (Modified AFIP Criteria) |
| | | Grading Criteria of Healey et al for Mucoepidermoid Carcinoma of Salivary Gland Origin |
| | | Risk Factors of de Brito Santos for Cervical Lymph Node Metastases in a Patient with a Parotid Carcinoma |
| | | Risk Factors of Sung et al Associated with Metastastic Adenoid Cystic Carcinoma Arising in the Head or Neck |
| | | Model of Carrillo et al for Predicting Recurrence of a Parotid Carcinoma |
| Tumors of the Head and Neck: Tumors of the Jaws |
| | | Prognostic Factors in Osteogenic Sarcoma of the Jaws |
| | | Classification of Odontogenic Carcinomas |
| Tumors of the Head and Neck: Laryngeal and Tracheal Tumors |
| | | The Symptomatic-Anatomic-Comorbid (SAC) Staging System of Feinstein et al for Cancer of the Larynx |
| | | Composite Laryngeal Recurrence Staging System (CLRSS) of Lacy and Piccirillo for Recurrent Laryngeal Squamous Cell Carcinoma |
| | | TNM Staging of Bhattacharyya for Tracheal Carcinoma |
| Tumors of the Thyroid and Parathyroid Glands |
| | | Prognosis in Medullary Carcinoma of the Thyroid |
| | | Staging for Papillary and Follicular Thyroid Carcinoma |
| | | MACIS Prognostic Score for Papillary Thyroid Carcinoma |
| | | AMES Prognostic Groups in Patients with Thyroid Carcinoma |
| | | The EORTC Thyroid Cancer Cooperative Group Prognostic Index for Thyroid Carcinoma |
| | | The AGES Prognostic Score for Papillary Thyroid Carcinoma |
| | | Prediction of Malignancy for Nonfollicular Thyroid Neoplasms Based on the Ultrasound Features of Koike et al |
| | | Risk Factors from the NCCN Guidelines for Stratifying Patients with a Well-Differentiated Thyroid Cancer |
| | | Prognostic Factors of Shoup et al for a Patient with Metastatic Differentiated Thyroid Carcinoma |
| | | The VAN and SAG Scores of Akslen for Evaluating a Patient with a Papillary Thyroid Carcinomas |
| | | Indicators of Ohshima et al for Performing a Bilateral Modified Radical Neck Dissection in a Patient with a Papillary Thyoid Carcinoma |
| | | Clinical Findings Suspicious for Thyroid Carcinoma in a Euthyroid Patient with a Solitary Thyroid Nodule |
| | | Prognostic Factors of Cushing et al for a Patient with Well-Differentiated Thyroid Carcinoma |
| | | Pretreatment and Posttreatment Scores of Yildirim for Predicting Risk in a Patient with a Differentiated Thyroid Carcinoma |
| | | Staging System of Shin et al for a Papillary Thyroid Carcinoma with Local Airway Invasion |
| | | Risk Factors of Ghossein et al for Recurrence of an Encapsulated Hurthle Cell Carcinoma of the Thyroid Gland |
| Lung Carcinoma |
| | | TNM Classification and Staging of Lung Carcinoma |
| | | Prognostic Staging System of Sagman et al for Small Cell (Oat Cell) Carcinoma of the Lung |
| | | Prognostic Factor Risk Index of Shinkai et al for Advanced Non-Small-Cell Lung Cancer |
| | | Prognostic Index for Patients with Non-Small Cell Lung Cancer |
| | | Criteria for Pulmonary Neuroendocrine Tumors |
| | | Clinical Severity Staging System for Lung Cancer of Feinstein and Wells |
| | | Prognostic Factors of Beasley et al for Pulmonary Atypical Carcinoid Tumors |
| | | Modified Scar Grade of Maeshima et al for Small Peripheral Lung Adenocarcinomas |
| | | Clinical Features of the Pancoast Syndrome in a Patient with Lung Cancer |
| | | Criteria of Gal et al from the AFIP for Pulmonary Fibrohistiocytic Tumors |
| | | Prognostic Factors of Albain et al from the Southwest Oncology Group (SWOG) for Extensive-Stage Non-Small-Cell Lung Cancer |
| | | Prognostic Factors of Paesmans et al for a Patient with Advanced Non-Small-Cell Lung Cancer |
| | | Prognostic Factors of Suzuki et al for a Patient with a Surgically Resected Non-Small Cell Lung Carcinoma |
| | | Grading Criteria of Suzuki et al for Non-Small Cell Carcinomas of the Lung |
| | | Model of Hoang et al for Predicting Survival in a Chemoniave Patient with Advanced Non Small Cell Lung Cancer Treated with Platinum-Based Doublet Chemotherapy |
| | | Pretreatment Prognostic Score of Maestu et al for a Patient with Small Cell Lung Cancer |
| | | Prognostic Factors of Takigawa et al for a Patient with Advanced Non-Small Cell Lung Cancer (NSCLC) |
| | | Prognostic Index of Vincent et al for Small Cell Lung Cancer |
| | | Prognostic Model of Cerny et al for a Patient with a Small Cell Lung Cancer (Manchester Score) |
| | | Prognostic Model of Souhami et al for a Patient with Small Cell Carcinoma of the Lung |
| | | Prognostic Model of Mandrekar et al for Advanced Non-Small Cell Lung Cancer (NSCLC) |
| | | Monitoring Serum Neuron-Specific Enolase (NSE) in a Patient with a Small Cell Carcinoma of the Lung |
| | | Prognostic Scores of Forrest et al for a Patient with Inoperable Non-Small-Cell Carcinoma of the Lung (Glasgow Prognostic Score) |
| | | Prognostic Indices of Muers et al for a Patient with Non-Small Cell Lung Cancer |
| | | Criteria of Martini and Melamed for the Diagnosis of Synchronous Primary Lung Carcinomas |
| | | Prognostic Factors of Ou et al for Survival in a Patient with Non-Small Cell Lung Cancer |
| Tumors of the Mediastinum and Thymus |
| | | Clinical Staging System for Thymoma of Masaoka et al |
| | | Prognostic Analysis of Thymoma of Pescarmona et al |
| | | TNM Classification for Thymoma |
| | | Prognostic Factors of Zisis et al for Survival in a Patient with a Completely Resected Thymic Epithelial Tumor |
| | | World Health Organization (WHO) Histologic Classification for a Thymic Epithelial Tumor |
| Tumors of the Heart |
| | | Prognostic Factors of Burke et al for Primary Sarcomas of the Heart |
| Breast Carcinoma |
| | | Elston's Modification for the Criteria of Bloom and Richardson in the Histologic Grading of Infiltrating Ductal Carcinoma |
| | | Prognostic Index of Haybittle et al for Infiltrating Ductal Carcinoma (Nottingham Prognostic Index, NPI) |
| | | Van Nuys Prognostic Index for Ductal Carcinoma In Situ |
| | | TNM Classification and Clinical Staging of Breast Carcinoma |
| | | Prognostic Factors in Breast Carcinoma |
| | | Scoring Breast Cosmesis Following Therapy |
| | | Absolute and Relative Contraindications to Breast Conservation Treatment with Radiation |
| | | Relative Risk for Subsequent Invasive Breast Cancer Associated with Changes Seen in Breast Biopsies |
| | | Evaluating a Woman's Risk of Developing Breast Cancer Based on Her Family's Cancer History |
| | | Grading Ductal Carcinoma in Situ Using the AFIP System of Tavassoli et al |
| | | Prognostic Score of Chevallier et al for Histological Node Negative Breast Carcinoma |
| | | Prediction of Metastases to Axillary Lymph Nodes in Women with Invasive Breast Carcinoma |
| | | The Model of Gail et al for Predicting the Probability of Developing Breast Cancer in White Women Examined Annually: Calculating the Relative Risk |
| | | The Model of Gail et al for Predicting the Probability of Developing Breast Cancer in White Women Examined Annually: Calculating the Absolute Risk |
| | | The Model of Claus et al for Predicting Cumulative Probability of Breast Cancer: First Degree Relatives with Breast Cancer |
| | | The Model of Claus et al for Predicting Cumulative Probability of Breast Cancer: Mother and Aunt with Breast Cancer |
| | | The Model of Claus et al for Predicting Cumulative Probability of Breast Cancer: Second Degree Relatives with Breast Cancer |
| | | The Model of Claus et al for Predicting Cumulative Probability of Breast Cancer: Relatives with Ovarian Cancer |
| | | The Prognostic Index of Yamamoto et al for Women with Metastatic Breast Carcinoma |
| | | Factors of Lambert et al for Predicting Nipple Involvement in Women with Breast Cancer |
| | | Standardized Instrument of Petrek et al for Detecting Lymphedema in a Patient with Breast Cancer Following Axillary Lymph Node Dissection |
| | | The Triple Test Score (TTS) for Palpable Breast Masses |
| | | Criteria of Rosen for Identification of Lymphatic Tumor Emboli in Breast Carcinoma |
| | | Histologic Grading of Phyllodes Tumor |
| | | 2 mm Size Rule of Tavassoli for Ductal Carcinoma in Situ (DCIS) |
| | | Factors Associated with Response to Neoadjuvant Chemotherapy in Women with Breast Carcinoma |
| | | Infiltrating Ductal Carcinoma with Extensive Ductal Carcinoma in Situ (DCIS) |
| | | The Modified Triple Test Score (MTTS) for a Palpable Breast Mass |
| | | Probability of Successful Mapping of the Axillary Sentinel Lymph Nodes for Breast Cancer Based on the Woman's Age and Body Mass Index (BMI) |
| | | Risk Factors for Breast Cancer in a Male |
| | | Decision Tree of Banerjee et al for Prognosis in Women with Breast Cancer |
| | | Clinical Factors of Clarke et al Affecting the Cosmetic Result in a Woman with Stage I or II Breast Cancer Treated by Biopsy and Irradiation |
| | | Indications for Performing a Mastectomy in a Woman with a Phyllodes Tumor |
| | | Nucleus Fibrotic Focus Fat Invasion (NNF) Classification of Hasebe et al for Invasive Ductal Carcinoma of the Breast |
| | | Model of Kattan et al for Predicting Mortality in a Woman with Breast Cancer Who Does Not Receive Adjuvant Therapy |
| | | Histologic Features of Stalsberg and Harmann for Infiltrating Tubular Carcinoma of the Breast Associated with Good Prognosis |
| | | Risk Categories from the 1998 St. Gallen Conference for Node Negative Breast Cancer in a Woman |
| | | Prognostic Factors of Kuru et al for Node Negative Breast Carcinoma in a Woman |
| | | Risk Categories from the 2001 St. Gallen Conference for Node Negative Breast Cancer in a Woman |
| | | Treatment Recommendations for a Woman with Operable Breast Cancer From the 2001 St. Gallen Conference |
| | | Model of Viale et al for Predicting Risk of Metastasis to Axillary Sentinel Lymph Nodes in a Patient with Breast Cancer |
| | | M.D. Anderson Prognostic Index (MDAPI) for Selecting a Woman with Breast Cancer for Breast Conserving Therapy After Neoadjuvant Chemotherapy |
| | | Risk Factors of Stolier and Grube for Nipple or Areola Involvement in a Woman with Primary Breast Carcinoma |
| | | Risk Factors of Gonzalez-Angulo et al Predictive for Distant Metastases in a Woman with Breast Cancer and a Complete Response to Neoadjuvant Chemotherapy |
| | | Nomogram of Rouzier et al for Predicting Complete Pathologic Response of a Breast Cancer to Preoperative Anthracycline Chemotherapy |
| | | Nomogram of Rouzier et al for Predicting the 5 and 10 Year Probabilities of Freedom from Distant Metastasis in a Woman with Residual Breast Cancer After Preoperative Anthracycline Chemotherapy |
| | | Histologic Grading of Lobular Carcinoma of the Breast Using the Bloom Richardson Score |
| | | Histologic Grades of Donnell et al for Angiosarcoma of the Breast |
| | | Factors of Chen et al for Identifying Increased Risk of Supraclavicular Lymph Node Metastases in Breast Carcinoma |
| | | Criteria of Isaacs et al for Counseling and Testing a Patient for BRCA1 and BRCA2 Mutations |
| | | Risk Factors of Dillon et al for Predicting Invasive Breast Cancer in a Woman with DCIS on Core Biopsy |
| | | Pedigree Assessment Tool (PAT) of Hoskins et al for Identifying a Woman at High Risk for Hereditary Breast Cancer |
| | | Predictors of Huo et al for Invasive Carcinoma in a Patient with Ductal Carcinoma in Situ (DCIS) Diagnosed on a Needle Core Biopsy |
| | | Tamoxifen Indication Score (TIS) of Rahman et al for a Woman with Breast Cancer |
| | | Criteria of Silver and Tavassoli for Minimally Invasive (Microinvasive) Breast Carcinoma |
| | | Histologic Features of Pleomorphic Invasive Lobular Carcinoma |
| | | Nomogram of Bevilacqua et al for Predicting Metastases to a Sentinel Lymph Node |
| | | J-Score for Reporting Estrogen Receptor Status by Immunohistochemistry for a Woman with Breast Cancer |
| | | Nomogram of Hanrahan et al for Survival in a Woman with a T1a,bN0M0 Breast Carcinoma |
| | | Allred Score for Reporting Estrogen Receptor Status by Immunohistochemistry for a Woman with Breast Cancer |
| | | Score of Acs et al for E-Cadherin Immunostaining in a Breast Carcinoma |
| Tumors of the Gastrointestinal Tract: Tumors of the Esophagus |
| | | Histologic Parameters for Grading Squamous Cell Carcinoma of the Esophagus |
| | | Clinical Risk Factors for Adenocarcinoma Arising in Barrett's Esophagus |
| | | Revised TNM Classification of Eloubeidi et al for Esophageal Carcinoma Based on Tumor Length |
| | | Grading Histologic Tumor Regression Following Preoperative Chemoradiotherapy for Esophageal Carcinoma |
| | | Prognostic Index of Chau et al for Patients with Locally Advanced or Metastatic Esophago-Gastric Cancer |
| | | Prognostic Factors of Rades et al for Overall Survival in a Patient with a Stage II or III Esophageal Carcinoma |
| | | Indications for Endoscopic Mucosal Resection (EMR) of a Superficial Carcinoma of the Esophagus |
| | | Classification of Siewert et al for Adenocarcinoma at the Gastroesophageal Junction |
| | | Risk Factors of Sauvanet et al for Complications in a Patient Undergoing Surgical Management of an Adenocarcinoma at the Gastroesophageal Junction (GEJ) |
| | | Classification of Radical Resections (R) for Adenocarcinoma at the Gastroesophageal Junction (GEJ) |
| | | Risk Score of Steyerberg et al for 30 Day Mortality After Surgery for Esophageal Cancer |
| Tumors of the Gastrointestinal Tract: Tumors of the Stomach |
| | | Prognostic Score of Marubini et al in Gastric Carcinoma |
| | | TNM Staging of Gastric Carcinomas |
| | | Prognostic Factors of Shiu et al for Adenocarcinoma of the Stomach |
| | | Prognostic Factors of Okada et al for Adenocarcinoma of the Stomach |
| | | Classification of the Gross Appearance in Gastric Carcinomas (Early and Borrmann Types) |
| | | Treatment Algorithm of Lowy et al for Gastric Cancer |
| | | Risk Factors of Marrelli et al for Liver Metastases After Surgical Resection of a Gastric Adenocarcinoma |
| | | Postoperative Nomogram of Kattan et al for Predicting Disease-Specific Survival in a Patient With Gastric Carcinoma and No Residual Disease (R0) |
| | | Indications of Soetikno et al for Endoscopic Mucosal Resection (EMR) of a Superficial Gastric Carcinoma |
| | | Postrecurrence Risk Score of Bennett et al for Predicting Survival in a Patient with Recurrent Gastric Carcinoma |
| | | Criteria of Gotoda et al for Local Therapy of an Early Gastric Cancer |
| | | Prognostic Factors of Adachi et al for a Patient with an Alpha Fetoprotein (AFP) Producing Gastric Carcinoma |
| Tumors of the Gastrointestinal Tract: Carcinomas of the Small Intestine, Large Intestine and Anus |
| | | TNM Staging of Colon Cancer |
| | | Doubling Time of CEA Concentrations and Prognosis in Recurrent Gastric and Colorectal Carcinoma |
| | | Prognostic Score of Diez et al for Colorectal Adenocarcinoma Based on Histopathologic Features |
| | | Hereditary Nonpolyposis Colorectal Cancer (HNPCC): Amsterdam Criteria and Lynch Classification |
| | | Grading and Prognostic System for Colon Carcinoma of Jass et al |
| | | Lifetime Risk for Colorectal Carcinoma According to Houlston et al |
| | | West Midlands Screening Criteria for a Person with a Family History of Colorectal Carcinoma |
| | | Hereditary Nonpolyposis Colorectal Cancer (HNPCC): Bethesda Guidelines |
| | | Management of the Patient with Adenocarcinoma in a Colonic Adenomatous Polyp |
| | | Risk Factors of Nascimbeni et al for Predicting Lymph Node Metastasis in Patients with T1 Carcinoma of the Colon or Rectum |
| | | Cumulative Prognostic Index of Petersen et al for a Patient with Duke's B Colon Carcinoma |
| | | UK National Health Service (NHS) and Department of Health Risk Criteria for Colon Cancer |
| | | Risk Factors of Merkel et al for Patients with Stage II Colon Carcinoma |
| | | Criteria of Bouzourene et al for Assessment of Tumor Regression After Preoperative Radiotherapy of Locally Advanced Rectal Carcinoma |
| | | Prognostic Index of Graf et al for Patients with Advanced Colorectal Carcinoma |
| | | Risk Stratification Tree of Radespiel-Troger et al for Predicting Recurrence After Curative Resection of Colon Carcinoma |
| | | Criteria of Cooper for the Diagnosis of a Squamous Cell Carcinoma of the Colon or Rectum |
| | | Risk Factors of Fujimoto et al for Liver Metastases in a Patient with Colorectal Carcinoma |
| | | ACPGBI (Association of Coloproctology of Great Britain and Ireland) Score for Predicting Mortality in a Patient with Colorectal Cancer |
| | | Predictors of Das et al for Downstaging a Rectal Cancer Treated with Preoperative Chemoradiation |
| Tumors of the Gastrointestinal Tract: Smooth Muscle and Stromal Tumors |
| | | Prognostic Factors in Extragastrointestinal Stromal Tumors |
| | | Risk Factors of Fletcher et al for Aggressive Behavior in Gastrointestinal Stromal Tumors (GIST) |
| | | Diagnosis of Spindle Cell Tumors of the Gastrointestinal Tract with Immunoperoxidase Staining |
| | | Gastrointestinal Stromal Tumor (GIST) Risk Score of Nilsson et al |
| | | Risk Factors of Van Glabbeke et al for Early or Late Resistance to Imatinib in a Patient with a Gastrointestinal Stromal Tumor (GIST) |
| | | Phenotypic Changes in a Gastrointestinal Stromal Tumor (GIST) After Therapy with Imatinib Mesylate |
| | | Criteria of Yokoi et al for Malignancy in a Gastrointestinal Stromal Tumor (GIST) |
| Hepatocellular Tumors |
| | | Okuda Staging System for Hepatocellular Carcinoma |
| | | Prognostic Factors in Advanced Hepatocellular Carcinoma |
| | | Prognostic Score of Iwatsuki et al to Predict Hepatocellular Carcinoma Recurrence After Liver Transplantation |
| | | Algorithm of Terkivatan et al for the Management of a Solitary Solid Liver Tumor |
| | | Hepatocellular Prognostic Index (HPI) of Lauwers et al for Patients with Completely Resected Hepatocellular Carcinomas |
| | | The Chinese University Prognostic Index (CUPI) for Hepatocellular Carcinoma |
| | | Molecular Classification of Hepatocellular Carcinoma Based on Estrogen Receptor Transcripts |
| | | Prediction Score of Yamanaka et al for Selecting Surgical Treatment of Liver Cancer |
| | | Prognostic System of the Cancer of the Liver Italian Program (CLIP) |
| | | Simplified T Classification of Vauthey et al for Hepatocellular Carcinoma |
| | | TNM Classification for Hepatocellular Carcinoma |
| | | The Pretreatment Extent of Disease (PRETEXT) System for Describing Hepatocellular Carcinoma |
| | | Criteria for Response to Therapy of the International Society of Pediatric Oncology Group for a Patient with Hepatocellular Carcinoma |
| | | The Barcelona-Clinic Liver Cancer (BCLC) Staging Classification for Hepatocellular Carcinoma |
| | | The French Classification of Chevret et al for Hepatocellular Carcinoma |
| | | Clinical Prognostic Model of Tan et al for Hepatocellular Carcinoma |
| | | Monitoring Strategy of Bruix et al for Hepatocellular Carcinoma in a Patient with Cirrhosis |
| | | Classification of the Children's Cancer Study Group (CCSG) for Hepatoblastoma |
| | | CAP (C-Reactive Protein, Albumin, Platelet Count) Score of Hashimoto et al for a Patient with Hepatocellular Carcinoma |
| | | Prognostic Score of Pawlik et al for Predicting Survival After Resection of a Large Hepatocellular Carcinoma |
| | | Criteria of Arrieta et al for the Diagnosis of Hepatocellular Carcinoma in a Patient with Cirrhosis Based on Serum Alpha Fetoprotein (AFP) Levels |
| | | Prognostic Index of Ikai et al for a Hepatocellular Carcinoma with a Tumor Thrombus in a Major Portal Vein |
| | | Modified Japan Integrated Scoring System (JISS) for a Patient with Hepatocellular Carcinoma |
| | | Prognostic Factors of D'Antiga et al for a Patient with a Hepatoblastoma |
| Tumors of the Bile Ducts and Gallbladder |
| | | Diagnosis of Cholangiocarcinoma in Patients with Primary Sclerosing Cholangitis Using the Serum Tumor Marker Score of Ramage et al |
| | | TNM Staging System of Okabayashi et al for Intrahepatic Cholangiocarcinoma |
| | | Classification of Bismuth and Corlette for Hilar Cholangiocarcinoma |
| | | Criteria for Identifying an Intrahepatic or Perihilar Cholangicarcinoma as Unresectable |
| | | Risk Factors for Gallbladder or Bile Duct Carcinoma |
| | | Prognostic Factors of Baton et al for Survival After Major Hepatectomy for Hilar Cholangiocarcinoma Type 3 or 4 (Advanced Klatskin Tumor) |
| | | Risk Factors of Shaib et al for Cholangiocarcinoma |
| Tumors of the Exocrine Pancreas |
| | | Prognostic Factors of Geer and Brennan in Patients with Pancreatic Adenocarcinoma |
| | | Prognostic Index of Ikeda et al for Patients with Locally Advanced, Nonresectable Pancreatic Carcinoma |
| | | Clinical and Laboratory Findings Associated with Poor Prognosis in Patients with Pancreatic Adenocarcinoma |
| | | Management Options for a Patient with Pancreatic Adenocarcinoma |
| | | Prognostic Index of Sawaki et al for a Patient with Metastatic Pancreatic Cancer Treated with Gemcitabine |
| | | Contraindications for Attempting Surgical Resection of a Pancreatic Adenocarcinoma |
| | | Cytologic Grading System of Eltoum et al for Pancreatic Adenocarcinoma |
| | | Nomogram of Ferrone et al for Disease-Specific Survival After Resection of a Pancreatic Adenocarcinoma |
| | | Risk Factors of Ferrone et al Associated with Survival in a Patient with Resectable Pancreatic Adenocarcinoma |
| | | Histologic Grading System of Hruban and Fukushima for a Pancreatic Adenocarcinoma |
| | | Histologic Features to Help Determining if Pancreatic Glands Are Benign or Malignant |
| Tumors of the Periampullary Region |
| | | TNM Classification of Carcinoma Arising at the Ampulla of Vater |
| | | Prognostic Factors of Kau et al for Periampullary Carcinomas |
| Islet Cell, Carcinoid and Neuroendocrine Tumors |
| | | Risk Factors in Rectal Carcinoid Tumors |
| | | Indications for Hemicolectomy in a Patient with an Appendiceal Carcinoid Tumor |
| | | Clinical Features of the Zollinger-Ellison Syndrome Associated with Neuroendocrine Gastrin Hypersecretion (Gastrinoma, Islet Cell Hyperplasia) |
| | | Vasoactive Intestinal Peptide Secreting Tumor (VIPoma, Pancreatic Cholera, WDHA) |
| | | Clinical Features of an Insulinoma |
| | | Clinical Features of the Glucagonoma Syndrome |
| | | Clinical Features of the Somatostatinoma Syndrome |
| | | Clinical Features of the Carcinoid Syndrome |
| | | Prognostic Factors of Shebani et al for Carcinoid Tumors Arising in the Gastrointestinal Tract |
| | | Prognostic Classification of Hochwald et al for Pancreatic Endocrine Neoplasms |
| | | Histologic Types of Solcia et al for Pancreatic Endocrine Tumors |
| | | Criteria of Deshpande et al for a Malignant Pancreatic Endocrine Tumor |
| | | TNM Staging Scheme of Ellison et al for Gastrinoma |
| | | Prognostic Factors of Haider et al for a Patient with an Extrapulmonary Small Cell Carcinoma |
| | | Histologic Grading Scheme of Rindi et al for a Foregut Neuroendocrine Tumor |
| | | TNM Classification of Rindi et al for a Malignant Neuroendocrine Tumor Arising in the Pancreas |
| Tumors of the Adrenal Gland |
| | | Separation of Benign vs Malignant Adrenal Cortical Tumors Based on the Criteria of Hough et al |
| | | Separation of Benign vs Malignant Adrenal Cortical Tumors Based on the Criteria of Weiss |
| | | Separation of Benign vs Malignant Adrenal Cortical Tumors Based on the Criteria of Slooten et al. |
| | | TNM Classification of Adrenal Cortical Carcinoma |
| | | Predictors of Stojadinovic et al for Disease Specific Survival in Patients with Adrenocortical Carcinoma |
| | | Separation of Benign vs Malignant Adrenal Cortical Tumors Based on the Modified Weiss Score of Aubert et al |
| | | Histomorphological and Molecular Criteria of Stojadinovic et al for Metastatic Adrenocortical Carcinoma |
| | | Algorithm of Blanes and Diaz-Cano for the Histopathologic Diagnosis of Proliferation Lesions of the Adrenal Cortex |
| Tumors of the Kidney |
| | | Fuhrman's Nuclear Grading System for Renal Cell Carcinoma |
| | | Modified Staging System of Robson for Renal Cell Carcinoma |
| | | TNM Staging System of the American Joint Committee on Cancer for Renal Cell Carcinoma |
| | | Prognostic Factors for Renal Cell Carcinoma |
| | | Prognostic Factors of Elson et al in Recurrent or Metastatic Renal Cell Carcinoma |
| | | Prognostic Factors of Motzer et al in Advanced Renal Cell Carcinoma |
| | | The UCLA Integrated Staging System (UISS) for Renal Cell Carcinoma |
| | | Prognostic Factors of De Forges et al for Patients with Metastatic Renal Cell Carcinoma |
| | | Mathematical Model of Zisman et al for Predicting Survival in a Patient with Renal Cell Carcinoma |
| | | Risk Group Analysis Algorithm of Zisman et al for Predicting Outcome in Patients with Surgically Resected Renal Cell Carcinoma |
| | | Prediction Model of Leibovich et al for Patients with Clear Cell Renal Cell Carcinoma After Radical Nephrectomy |
| | | SANI Score of Leibovich et al for Predicting Survival in Patients with Metastatic Renal Cell Carcinoma After Nephrectomy and Immunotherapy with Interleukin-2 |
| | | Prognostic Factors of Motzer in Previously Treated Patients with Metastatic Renal Cell Carcinoma |
| | | Prognostic Factors of Malhi et al for Patients with Metastatic Renal Cell Cancer |
| | | Risk Score of Hanninen et al for a Patient with Metastatic Renal Cell Carcinoma |
| | | Prognostic Score of Palmer et al for a Patient with Advanced Renal Cell Carcinoma Treated with Recombinant Interleukin-2 |
| | | The Stage, Size, Grade and Necrosis (SSIGN) Score of Frank et al for Predicting Survival in a Patient with a Clear Cell Renal Cell Carcinoma |
| | |